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Abstract
Objective
In 2016, Catalonia experienced a pediatric brainstem encephalitis outbreak caused by en-
terovirus A71 (EV-A71). Conventional testing identified EV in the periphery but rarely in CSF.
Metagenomic next-generation sequencing (mNGS) and CSF pan-viral serology (VirScan)
were deployed to enhance viral detection and characterization.
Methods
RNA was extracted from the CSF (n = 20), plasma (n = 9), stool (n = 15), and nasopharyngeal
samples (n = 16) from 10 children with brainstem encephalitis and 10 children with meningitis
or encephalitis. Pathogens were identified using mNGS. Available CSF from cases (n = 12) and
pediatric other neurologic disease controls (n = 54) were analyzed with VirScan with a subset
(n = 9 and n = 50) validated by ELISA.
Results
mNGS detected EV in all samples positive by quantitative reverse transcription polymerase
chain reaction (qRT-PCR) (n = 25). In qRT-PCR-negative samples (n = 35), mNGS found
virus in 23% (n = 8, 3 CSF samples). Overall, mNGS enhanced EV detection from 42% (25/60)
to 57% (33/60) (p-value = 0.013). VirScan and ELISA increased detection to 92% (11/12)
compared with 46% (4/12) for CSF mNGS and qRT-PCR (p-value = 0.023). Phylogenetic
analysis confirmed the EV-A71 strain clustered with a neurovirulent German EV-A71. A single
amino acid substitution (S241P) in the EVA71 VP1 protein was exclusive to the CNS in one
subject.
Conclusion
mNGS with VirScan significantly increased the CNS detection of EVs relative to qRT-PCR,
and the latter generated an antigenic profile of the acute EV-A71 immune response. Genomic
analysis confirmed the close relation of the outbreak EV-A71 and neuroinvasive German EV-
A71. A S241P substitution in VP1 was found exclusively in the CSF.
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In early 2016, an outbreak of enterovirus A71 (EV-A71) in
Catalonia caused more than 100 pediatric cases of neurologic
disease, ranging from aseptic meningitis to brainstem enceph-
alitis with or without myelitis.1 Quantitative reverse transcrip-
tion polymerase chain reaction (qRT-PCR) for EV with
genotyping of peripheral blood, respiratory, and gastrointesti-
nal samples, but not CSF, identified EV-A71 in 40 of 57 sub-
jects. Other EVs were also found in 7 of 57 subjects, including
echovirus 30 (E-30), coxsackievirus (CV) B1, and CV A10.
Although unable to type the EVs, the BioFire FilmArray
Meningitis/Encephalitis panel detected EV in the CSF of 4 of
20 subjects with brainstem encephalitis.2 The EV-A71 strain
detected in this study was subtyped as subgenogroup C1, and
phylogenetic analyses showed it was closely related to an EV-
A71 strain associated with a 2015 German case of brainstem
encephalitis.3–5 EV-A71 and other EV-related neurologic dis-
ease outbreaks were also reported in France and Denmark in
2016.6,7 Although EV-A71 was detected in peripheral body
sites of many of these cases, EV-A71 was only identified in the
CSF of 0.02% of subjects in the German study, 3% in the
Danish study, and 14% in the French study.
Despite the presence of EV in peripheral samples, questions
remained about the Catalonia outbreak. Because pan-EV
qRT-PCR was negative in the CSF of subjects with brainstem
encephalitis,1,8 concern persisted that neurologic symptoms
may have been caused by a parainfectious mechanism or an
unidentified coinfection. In addition, standard qRT-PCR
assays on peripheral samples recovered small segments of the
EV-A71 genome, thereby limiting the ability to assess for viral
mutations that may have modulated neurovirulence.
To address these concerns, we deployed metagenomic next-
generation sequencing (mNGS) on samples from the 2016
Catalonia outbreak. mNGS is an unbiased assay that can si-
multaneously identify nucleic acid from viruses, fungi, bacte-
ria, and parasites in subjects with neurologic symptoms. As
opposed to traditional PCR assays that amplify limited and
usually highly conserved regions of a microbe’s genome, the
entire genome of a pathogen can often be recovered with
mNGS. This makes it possible to identify genomic changes in
the virus that may correlate with increased neurovirulence or
reveal strain divergence.9 Here, we deployed mNGS on CSF,
nasopharyngeal (NP), plasma, and stool samples from chil-
dren affected by neurologic disease during the 2016 Catalonia
outbreak. This allowed us to screen for all EVs and for pos-
sible coinfections while simultaneously comparing EV
genomes for any differences between the subjects with
brainstem encephalitis and other manifestations of neurologic
disease (i.e., meningitis with or without encephalitis with self-
limited and short-lasting symptoms). We supplemented our
investigations with an enhanced version of a previously pub-
lished assay that comprehensively assesses for antiviral anti-
bodies using phage display (VirScan) and performed
orthogonal confirmation with EV ELISA.10–12
Methods
Cohort
The cohort consisted of 20 pediatric cases of EV-related
neurologic diseases. Specifically, we selected 10 children di-
agnosed with brainstem encephalitis or encephalomyelitis and
10 children with aseptic meningitis or uncomplicated en-
cephalitis. Cases were recruited from the Hospital Sant Joan
de Deu, University of Barcelona, between April and June
2016. TheHospital Sant Joan de Deu is a 300-bed tertiary care
hospital for high-complexity patients across a catchment area
with a pediatric population of;300,000 and has participated
in a Spanish EV molecular surveillance network since 2010.
EV-related neurologic disease was defined as the detection of
EV by a pan-EV qRT-PCR assay or BioFire FilmArray
Meningitis/Encephalitis panel8,13,14 in at least one sample
from a subject suffering acute neurologic disease in the ab-
sence of another clear cause.1 Case definitions of the World
Health Organization’s A Guide to Clinical Management and
Public Health Response for Hand, Foot and Mouth Disease
(HFMD), detailed in table e-1 (links.lww.com/NXI/A216),
were followed by a group of trained pediatricians to classify
cases.
Case demographics and clinical syndromes are described in table
1. Deidentified samples from encephalomyelitis/brainstem en-
cephalitis (n = 10) and meningitis/encephalitis (n = 10) were
transferred to UCSF on dry ice and stored at −80°C. The
specimens from cases included CSF, serum, NP, and stool
samples (figure 1 and table e-2, links.lww.com/NXI/A216).
Among the 60 samples, 35 were EV-negative by clinical pan-EV
qRT-PCR (table e-2). The subjects 1–10 were negative by the
BioFire FilmArray Meningitis/Encephalitis panel.2 All EV-
positive subjects (by clinical PCR) were genotyped at the En-
terovirus Unit of the Spanish National Centre for Microbiology
according to a previously described procedure.15 For VirScan
controls, we used CSF from pediatric subjects with other neu-
rologic diseases (ONDs). VirScan and available clinical data have
been previously published on this control cohort.10
Standard protocol approvals, registrations,
and patient consents
The institutional ethics board approved the study, and in-
formed consent was obtained from parents or caretakers.1
Glossary
CV = coxsackievirus;mNGS =Metagenomic next-generation sequencing;NP = nasopharyngeal;OD = optical density;OND =
other neurologic disease; qRT-PCR = quantitative reverse transcription polymerase chain reaction;UTR = untranslated region.
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Metagenomic sequencing library preparation
After samples were thawed, RNA was immediately extracted.
The plasma, stool, and NP samples were homogenized with
Omni-International’s 2.8-mm ceramic bead kit and the Tis-
sueLyser II (Qiagen) for 5 minutes at 15 Hz. RNA isolation
from the CSF samples (250 μL/sample), the plasma samples
(250 μL/sample), the NP swab samples, and 2 water controls
were performed using the Direct-zol RNA MicroPrep with
TRI reagent (Zymo Research) into 20 μL of nuclease-free
water (ThermoFisher Scientific). Homogenized stool sam-
ples (250 μL/sample) were extracted using the RNeasy
PowerMicrobiome Kit (Qiagen) on a Qiacube (Qiagen) into
100 μL of RNase-free water along with a water control. Se-
quencing libraries were prepared as described previously.16
The libraries were subjected to Depletion of Abundant
Sequences by Hybridization, described previously, to remove
human mitochondrial cDNA.17 The pooled library was size-
selected using AMPure beads (Beckman Coulter), and con-
centration and quality were determined using a Fragment
Analyzer (Advanced Analytical Technologies). The samples
were sequenced on an Illumina HiSeq 4000 instrument using
140/140 base pair (bp) paired-end sequencing.
Sequencing libraries produced from the CSF samples were
prepared together (including a water control). Sequencing
libraries from the plasma, stool, and NP swab samples were
prepared together with their respective water controls. The
water controls for CSF and NP samples contained no EV
reads (i.e., sequences). The stool water control, which had
been pooled for sequencing with stool samples containing EV
reads, had 0.7 EV reads per million (rpM). To differentiate
whether the EV reads present in the stool water control
stemmed from sample contamination during library prepa-
ration or from sequencer contamination because of barcode
hopping,18 we resequenced the same stool water control li-
brary independent of the stool samples. When sequenced
separately, we found no EV reads in the stool water control.
This suggested that the EV reads originally detected in the
stool water control resulted from barcode hopping and not
from sample contamination during library preparation. To
remove any potential that physical cross-contamination had
occurred between libraries, we resequenced a subset of the
original libraries with pathogen abundance below 0.7 rpM and
only considered a case positive if the pathogen was detected in
both sequencing runs. If a pathogen was only detected in
a sample in one of the 2 sequencing runs, it was considered to
have 0 EV reads in that sample.
mNGS bioinformatics
Sample sequences were analyzed for pathogens using a cus-
tom pathogen identification pipeline, as previously de-
scribed.19 Sequences that mapped to the EV genus were
assembled de novo using the Geneious version 10.2.3 and St.
Petersburg genome assembler (SPAdes) version 3.10.0.20
Phylogenetic trees were created in Geneious using a multiple
sequence comparison by log expectation (MUSCLE) or
multiple alignment using fast Fourier transform (MAFFT)
alignment algorithm, followed by the Geneious Tree Builder
tool with Neighbor-Joining build method.3,21 Bootstrapping
was performed with 100 replicates. Statistics comparing the
degree of concordance between research-based mNGS results
and standard clinical diagnostic testing and comparing direct
Table 1 Summary of subject group demographics and
clinical data
Cases,
Total = 10
Controls,
Total = 10
Mean age (mo)a 22.7
(18.1–31.2)
10.8 (0.9–37.5)
Sex (male) 4 6
Systemic symptoms
Fever 10 10
Vomiting 6 4
Diarrhea 2 1
Exanthema 5 3
Enanthema 8 2
Neurologic symptoms
Meningismus 2 3
Irritability 2 2
Lethargy 8 4
Headache 1 2
Myoclonic jerks 6 0
Tremor 5 0
Ataxia 9 0
Paresis 3 0
Nystagmus and/or strabismus 1 0
Bulbar palsy 2 0
Medullary symptoms 3 0
WHO clinical classification
Meningitis 0 7
Encephalitis 0 3
Brainstem encephalitis 8 0
Encephalomyelitis 2 0
EV results by clinical Pan-EV qRT-PCR
(positive/total)
CSF 0/10 5/10
Plasma 0/7 0/2
Nasopharyngeal sample 8/9 3/7
Stool 5/9 4/6
Abbreviation: EV = enterovirus.
a Median (interquartile range).
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Figure 1 Summary of mNGS diagnostics: improvement over traditional clinical testing
(A) Comparison of mNGS and qRT-PCR detection of EV-A71, E-30 and CVB in CSF, NP, and fecal samples. Statistics performed using the Fisher exact test, with
orangeandbluep-values correspondingwithmNGSandqRT-PCR results, respectively. (B) Comparisonof detection levels for eachdifferent experiment,with rpM
representing mNGS and Ct values for qRT-PCR. Triangles denote samples identified bymNGS but not qRT-PCR. Statistics performed using a Mann-Whitney test.
(C) Heatmap of each individual subject with each body site represented. Boxes with 2 colors represent codetections of different viral species. (D) Comparison of
mNGS detection rates to qRT-PCR. Statistics performed using theMcNemar test. CVB = Coxsackievirus B; E-30 = echovirus 30; EV-A71 = enterovirus A71; mNGS =
metagenomic next-generation sequencing; NP = nasopharyngeal; qRT-PCR = quantitative reverse transcription polymerase chain reaction.
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and indirect testing methods results were performed using the
Mann-Whitney and McNemar statistical tests.
Pan-viral CSF serologic testing with VirScan
We constructed a T7 bacteriophage display library com-
prising 481,966 sixty-two amino acid peptides with 14
amino acid overlap tiled across full-length vertebrate,
mosquito-borne, and tick-borne viral genomes downloaded
from UniProt and RefSeq databases in February 2017, as
previously described (VirScan).10,11 VirScan libraries were
incubated with 2 μL of CSF overnight, immunoprecipitated
with protein A/G beads (ThermoFisher Scientific) for 2
rounds, and sequenced as previously described.10 We nor-
malized individual peptide counts and expressed them as
reads per 25,000 reads sequenced (rpqK). A sample was
considered EV positive if the total EV rpqK value was
greater than the mean signal in the OND controls plus
one SD.
Enterovirus ELISA validation
To validate our VirScan results, we generated recombinant
EV viral protein 1 (VP1) from EV-A71 and EV-D68, given
that complex and cross-reactive serologic responses to EVs
are known to occur in subjects and performed 2 independent
ELISAs on each sample and considered the higher value, as
previously described.10 The signal was measured as the optical
density (OD) at 450 nm and reported after background
subtraction (background OD = 0.05). A sample was consid-
ered positive if the OD was greater than 3 times the
background.
Data availability
Assembled viral sequences have been deposited in GenBank
(MH484066-MH484076, MN515037), and nonhuman reads
have been deposited in the National Center for Bio-
technology Information (NCBI) Sequence Read Archive
BioProject database (PRJNA504776).
Results
Traditional clinical testing vs research mNGS
We obtained an average of 21.8 million (range 4.53–61.1
million) 140 bp paired-end reads per sample (table e-1, links.
lww.com/NXI/A216).
As expected, EV-A71 was the most common virus detected
across all samples (figure 1A). In the CSF, however, EV-A71
detection remained low relative to NP and fecal testing. By
pan-EV qRT-PCR, 0/20 cases were positive in the CSF vs 10/
16 in NP and 9/15 in fecal samples (p-value < 0.001 for both
comparisons by the Fisher exact test). With mNGS, 3/20
cases were positive in the CSF vs 13/16 in NP and 10/15 in
fecal samples (p-value < 0.001 and p = 0.003 by the Fisher
exact test). There was no statistically significant difference
observed in the number of samples testing positive by NP or
fecal testing (p = 1.0 for qRT-PCR and p = 0.43 for mNGS by
the Fisher exact test). When EV-A71 was present in the CSF,
the number of reads detected was lower than for the other
2 EVs we found, highlighting the difficulty of detecting EV-
A71 in CSF (figure 1B). The mean read count for E-30 was
greater in the CSF than that for EV-A71 (mean rpM
107.28, range 16.24–337.8 vs 0.23, range 0.06–0.55, p-
value = 0.057 by the Mann-Whitney test). We detected
CVB in 1 case which, such as E-30, was at a much higher
abundance than EV-A71 (32.25 rpM). We did uncover
coinfection with more than one EV in 5 subjects (figure
1C). Overall, we tested 60 samples by both mNGS and
qRT-PCR. mNGS found EV reads in 100% of qRT-PCR
positive samples (n = 25). mNGS detected EV in an ad-
ditional 22% (n = 8) of samples negative by qRT-PCR,
a statistically significant improvement in detection rate for
mNGS vs qRT-PCR (Figure 1D, p = 0.01 by the McNemar
test).
Phylogenetics
Full-length EV-A71 (n = 7), E-30 (n = 4), and CV-B virus
(n = 1) genomes (coverage depth range 22-2,296x) were
assembled as described in the Methods. All 7 EV-A71
genomes were essentially identical to the German neuro-
invasive EV-A71 strain (Genbank KX139462.1, 99.3%–99.4%
nucleotide similarity and 99.7%–99.8% amino acid similarity,
figure 2A). In addition, we reproduced a previous but more
limited phylogenetic analysis showing greater similarity in the
VP1 sequence between the neurovirulent EV-A71 in Cata-
lonia and other neurovirulent EV-A71 strains detected in
Germany, China, and West Africa as compared with preout-
break HFMD EV-A71 in Spain (figure 2B).3,22–24
To determine the degree of divergence of neurovirulent EV-
A71, E-30, and CV-B from their respective viral species, we
built a phylogenetic tree using the Catalonia genomes and
8,841 full-length EV genomes from the NCBI’s GenBank
database (Accessed February 2018) clustered at 95% simi-
larity. Because we detected more than one EV species in 5
subjects and because EVs are known to recombine, we used
this phylogenetic analysis to determine whether any obvious
interspecies recombination events had occurred.25,26 How-
ever, all 3 viruses clustered within their own species without
any major deviation (figure 2C).
Last, an EV-A71 genome assembled from a CSF sample was
compared with EV-A71 genomes derived from the same
subject’s stool and NP samples (subject 16). A single amino
acid substitution (S241P) in the VP1 region was found only in
the CSF, not the 2 peripheral sites. Indeed, all of the EV-A71
genomes identified in peripheral body sites from this study
had a serine in position 241 (figure 2D).
VirScan increases CSF detection of enterovirus
Although mNGS improved the detection of EVs across our
20 subjects compared with traditional qRT-PCR, uncovered
EV coinfections in 5 instances, and enabled phylogenetic
and mutational analyses, detection of EV-A71 in the CSF
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was more difficult than in the NP or fecal samples, as de-
scribed above. Therefore, we deployed VirScan for com-
prehensive antiviral antibody detection in the CSF. After
performing VirScan on 12 cases and 54 pediatric controls
with ONDs, the only significantly enriched viral family in
our cases was Picornaviridae (figure e-1A, links.lww.com/
NXI/A215 and table e-3, links.lww.com/NXI/A216, mean
rpqK was 2,366 in cases vs 224 in controls, p-value < 0.001
by the Mann-Whitney with Bonferroni correction). Within
Picornaviridae, the genus Enterovirus was the most enriched
(figure e1, B and C, and table e-4, median proportion of
reads 0.09 in cases vs 0.002 in controls, p-value < 0.001 by
the Mann-Whitney with Bonferroni correction). To de-
termine the genomic location of enriched EV antigens in
VirScan, we used BLASTp to map all genus Enterovirus
peptides against a model EV-A71 genome (Genbank Ac-
cession AXK59213.1), recognizing that not all EV subject
antibodies are likely to be truly EV-A71 specific. The loca-
tion and strength of the EV antigen response detected in
cases by VirScan is shown normalized against controls, with
immunodominant regions visible in VP1 and 3D (figure 3A
and table e-5, links.lww.com/NXI/A216). The pattern of
EV antigen targeting appears to be highly conserved and
similar to a group of previously published pediatric acute
flaccid myelitis cases predominantly from the United States
(figure 3A, red overlay).10
We next confirmed the EV VirScan results in a subset of
cases with remaining CSF using an EV VP1 ELISA. The EV
ELISA was confirmatory in all of the cases detected by Vir-
Scan (6/6). Thus, we considered the other EV cases
detected by VirScan for which there was insufficient CSF to
do confirmatory ELISA positive as well (n = 2 cases and n = 1
OND control were positive by VirScan but had insufficient
CSF remaining for confirmatory ELISA). In addition, EV
ELISA was positive for 3 cases in whom the amount of EV
signal by VirScan was below the threshold we set to consider
a sample positive. In total, 9/54 (17%) of the pediatric OND
controls were positive for CSF EV antibodies. Of note, EV
antibody detection by VirScan was not confirmed by EV
Figure 2 Phylogenetic and Genomic Analysis of EV-A71
(A) Phylogenetic tree of full-length viral genomes for enterovirus A71, echovirus 30, coxsackievirus B, and rhinovirus isolated fromCSF (L), stool (F), andNP (N)
compared with the German neuroinvasive strain (KX139462.1). Rhinovirus obtained from subjects acts as the root. The number refers to the subject. (B)
Confirmation of clinical VP1 testing that the Catalonian EV-A71 viral protein 1 (VP1) gene is most closely related to a neuroinfectious German strain. Blue =
neuroinvasive EV-A71, Orange = HFMD EV-A71. (C) Phylogenetic tree of 545 EV genomes from every species highlighting the relatedness between the EV
strains discovered in this outbreak. (D) Protein alignment of the VP1 gene highlighting the S241P mutation found exclusively in the CSF of subject 16. Scale
bars indicate nucleotide substitution rate per position. EV-A71 = enterovirus A71; F = fecal; NP = nasopharyngeal.
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ELISA in one OND control. This subject had limited clinical
information available, and the EV-A71 ELISA had detectable
signal above the background but was not above the con-
servative threshold we used to determine whether a sample
was positive.
We found that we were able to detect CSF EV antibodies
using VirScan or EV VP1 ELISA, regardless of whether EV
had been previously detected in the CSF by mNGS or qRT-
PCR (figure 3B, p-value = ns by Mann-Whitney). EV was
especially difficult to detect in the CSF of subjects with
brainstem encephalitis using mNGS or qRT-PCR (figure
3C). Therefore, we asked whether EV detection in brainstem
encephalitis could be improved with EV VirScan or ELISA.
Indeed, serologic testing with CSF VirScan or ELISA was
able to improve detection of EV in brainstem encephalitis
(figure 3D and table e-6, links.lww.com/NXI/A216, and
table e-7, links.lww.com/NXI/A216, p-value = 0.07 by the
Fisher exact test).
Discussion
The original description of the 2016 pediatric brainstem en-
cephalitis outbreak in Catalonia identified EV-A71 as the likely
etiologic agent. However, this conclusion was tempered because
(1) there were multiple cocirculating EVs present during the
outbreak and (2) EV-A71 was not identified in the CSF of most
children with brainstem encephalitis. Identifying EVs in pe-
ripheral body sites of children with severe neurologic disease but
failing to find it in the CSF mirrors both the recent North
American outbreak of acute flaccid myelitis associated with EV-
D6821 and outbreaks of EV-A71 neurologic disease.27,28 Here,
we used mNGS and serologic testing with VirScan and
Figure 3 VirScan Identifies immunodominant enterovirus antigens and improves the detection of CSF enterovirus in
encephalomyelitis/brainstem encephalitis
(A) VirScan identified 136 unique, enriched viral antigens with taxonomies linking them to genus Enterovirus. We mapped 123 of these 136 peptides with
BLASTP to a reference EV-A71 genome (Genbank Accession AXK59213.1), as described previously9 (coding genes in light blue, non-coding genes in orange).
Mapping revealed the relative locations of the EV antigens identified in the Catalonia cases (graphed blue shading) across the EV genome, which appeared
remarkably conserved, as seen previously in pediatric acute flaccidmyelitis (graphed light red shadingwith overlap appearing gray).10 (B) Violin plot revealing
enrichment for EV antigens by VirScan and EV VP1 antigen by ELISA in Catalonia cases, regardless ofwhether an EV had been previously identified bymNGSor
qRT-PCR (p = ns for both comparisons). In both groups, EV detection was significantly greater than in the pediatric OND controls (p < 0.001 for all comparisons
as indicated). TheMann-Whitney test was used, with Bonferroni correction for VirScan. (C) Differences in virus detection for subjects with encephalomyelitis/
brainstem encephalitis or encephalitis/meningitis. The detection of CSF EV bymNGS or qRT-PCRwas low (0/10). (D) VirScan or ELISA improved EV detection in
encephalomyelitis/brainstemencephalitis (0/6 vs 5/6, p = 0.07 by theMcNemar test). CSF = cerebral spinal fluid; EV = enterovirus;mNGS =metagenomic next-
generation sequencing; NP = nasopharyngeal; OND = other neurologic disease.
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confirmatory EV ELISA to further investigate samples from the
Catalonia outbreak to enhance detection of pathogens, especially
in the CSF.
mNGS identified EV-A71 in the CSF of 3 subjects not detected
by qRT-PCR. EV-A71 abundance in the CSF was very low
(range 0.06–0.55 rpM) comparedwith other EVs detected in the
CSF in this study (i.e., E-30 and CVB). In addition, only 2.4%
(4/166) of the EV-A71 reads mapped to the 59 untranslated
region (UTR) targeted by the primers used in the clinical qRT-
PCR assay. Because mNGS can identify EV sequences from any
part of the viral genome, this may help explain its improved
sensitivity over the more targeted clinical qRT-PCR and the
BioFire FilmArray Meningitis/Encephalitis panel assays.1,8
In addition, mNGS also identified 5 subjects coinfected by 2
different EVs, and 2 of these subjects had brainstem en-
cephalitis. Owing to the small number of subjects in our study,
we are not able to determine whether coinfection contributed
to disease severity. These findings highlight that in the midst
of an outbreak, unbiased mNGS can detect coinfections, and
future studies may uncover ways in which coinfections affect
clinical presentations and outcomes.
A limitation of this study is that because of sample availability,
we did not perform orthogonal confirmation of themNGS-only
virus identifications. As a result, our evaluation of the perfor-
mance of the mNGS assay is vulnerable to incorporation bias
because the gold standard by which we are evaluating its per-
formance includes the mNGS results.29 However, because we
tested low abundance samples on 2 independent sequencing
runs, we are confident that even the low levels of EV detected by
mNGS in some samples did not result from contamination
during sample preparation or from barcode hopping.
Through mNGS, we added significant new knowledge about
neurovirulent EV-A71, including 7 full-length genomes. The
assembled neurovirulent EV-A71 genomes were related to
other neurovirulent EV-A71 strains detected in Germany, West
Africa, and China rather than preoutbreak Spanish EV-A71
strains associated with HFMD. Interestingly, we found that the
EV-A71 strain circulating in Catalonia appeared to be most
closely related to the neurovirulent German strain, followed by
theWest African and thenChinese strains.22 TheGerman strain
reported in 2015 clusters within the C1 subgenogroup when
comparing VP1 regions. However, the 59 UTR clusters more
closely with B3 and C2-like strains and the P2 and P3 regions
cluster with C4 strains related to strains reported in China.3
In a single subject, we discovered a single amino acid substitution
(S241P) that was present only in EV-A71 sequences derived
from the CSF and not from viral sequences in the periphery of
that same subject. This substitution was not seen in any of the
other EV-A71 viruses sequenced from the same outbreak nor
was it found in any of the EV-A71 VP1 sequences compared in
figure 2B. An amino acid substitution (S241L) at this location
has been previously reported to be associated with increased
virulence.30 However, those authors also identified coincident,
additional mutations that increased the virus’s ability to use the
P-selectin glycoprotein ligand-1 (PSGL-1) cell receptor.30–33
Here, the S241P mutation we observed occurs without the
mutation at position 145 that is required for PSGL-1 binding,
suggesting that this variant of unknown significance at position
241 may affect virulence in a PSGL-1 independent manner.
Although we were able to obtain EV-A71 sequences in the CSF
from subjects 12 and 17, they did not span position 241 of VP1.
No CSF remains from these subjects to obtain additional se-
quence information. Although the clinical and functional sig-
nificance of the S241P mutation remains uncharacterized, this
study highlights the importance of acquiring viral nucleic acid
directly from the CNS, as opposed to the periphery alone.
Owing to the limitations of direct detection of viral pathogens
using nucleic acid-based methods, we used VirScan to com-
prehensively profile CSF antiviral antibodies. This technique
has previously shown utility in the diagnosis of encephalitis
without a clear etiology.12 We show that antibodies directed
toward the genus Enterovirus, but not toward other viruses,
were present in the CSF of 8/12 cases. When we further ex-
amined a subset of these cases with an EV ELISA and com-
bined the results with VirScan, we found evidence for EV
antibodies in 11/12 (92%) cases from the Catalonia outbreak
vs just 9/54 (17%) pediatric OND controls, with significantly
improved detection of brainstem encephalitis due to EV. Al-
though we are able to detect antibodies to EVs broadly, VirScan
and ELISA detected antibodies targeting highly conserved
segments of EVs and thus did not allow for consistent viral
typing. In addition to detecting CSF antibodies to EV, our
analysis uncovered immunodominant epitopes at VP1 and 3D,
similar to what we found previously in EV-associated acute
flaccid myelitis.10,34 However, evaluation of linear peptides
from other regions of the EV genome may be more fruitful for
subtyping EV infections34 and future work with natively folded
EV proteins may also better serologically type EVs.
Although mNGS can detect a variety of pathogens in the
CSF,19,35–37 there have been few reports on the actual diagnostic
yield of mNGS of CSF compared with traditional assays such as
pathogen-specific PCR and the BioFire FilmArray Meningitis/
Encephalitis panel. In our study, mNGS was more sensitive in
cases with very low EV read abundance.38 Furthermore, identi-
fying an EV-A71 closely related to strains previously associated
with neurologic disease in Germany, West Africa, and China in
the CSF of 3 additional subjects provides strong evidence that
the Catalonia outbreak was because of neuroinvasive EV. Al-
though the experiments described herein used a research-based
CSF mNGS assay, a clinically validated CSF mNGS assay with
an approximate 7-day turnaround time was recently evaluated in
a multicenter prospective study and is now clinically available.38
Thus, the role of mNGS in individual patient care and public
health outbreak investigations will likely expand.
Similarly, the detection of CSV EV antibodies in many of
these subjects supports our findings of EV nucleic acid in the
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CSF while also providing more information about the im-
mune response against EV. A limitation of the VirScan
method is that we are unable to distinguish between anti-
bodies that have been synthesized intrathecally vs peripheral
synthesis, followed by transudation across the blood-brain
barrier. Furthermore, it is difficult to definitively say whether
these anti-EV IgG antibodies developed in response to this
particular outbreak. However, the markedly lower levels of
CSF EV antibodies in our pediatric OND control pop-
ulation, many of whom also had blood-brain barrier com-
promise, support our contention that the high levels of CSF
EV antibodies in the cases result from a CNS EV infection
and not simply from anti-EV antibodies formed in the pe-
riphery in response to the many peripheral EV infections
children contract.
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